High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-Risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment
Information source: National Taiwan University Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Endoscopy; Peptic Ulcer; Bleeding; Proton Pump Inhibitors
Intervention: High dose pantoprazole infusion (Drug); Standard dose pantoprazole infusion (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: National Taiwan University Hospital Overall contact: Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com
Summary
The study was designed to evaluate the efficacy an adjuvant use of standard dose or high
dose of proton pump inhibitor after combined endoscopic hemostasis therapy.
Clinical Details
Official title: High Dose Versus Standard Dose Proton Pump Inhibitor in High-Risk Bleeding Peptic Ulcers After Endoscopic Epinephrine Injection and Heat Probe Thermocoagulation/Hemo-Clip Hemostasis: A Prospective Randomized Comparative Study
Study design: Treatment, Randomized, Single Blind (Subject), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Primary outcome: rate of initial hemostasis and the rate of recurrent bleeding
Secondary outcome: need for surgical intervention to control bleeding, transfusion requirements, length of hospital stay (in days), and 30-day mortality
Detailed description:
Acute peptic ulcer bleeding remains the most common cause of acute upper gastrointestinal
bleeding. Endoscopy serves as a tool for initial diagnosis and triage and also a tool for
immediate hemostasis, especially for high-risk lesions. High-risk lesions include peptic
ulcers with active spurting vessel, oozing vessel, or NBVV, nonbleeding visible vessel.
Current modalities of endoscopic hemostasis include epinephrine injection, endoscopic
coaptive thermocoagulation, hemoclipping. Endoscopic hemostasis has been documented by a
number of clinical studies to be effective in decreasing rebleeding, need for emergency
surgery, decreasing hospitalization days. Current evidence also shows that combination
therapy with epinephrine injection and heater probe thermocoagulation/hemo-clip hemostasis
is more effective than epinephrine injection alone or than heater probe thermocoagulation
alone, or than hemoclip hemostasis alone. Studies showed a high dose intravenous proton pump
inhibitor infusion after initial endoscopic hemostasis reduced recurrent ulcer bleeding.
However, it was still controversial whether an adjuvant use of standard-dose proton pump
inhibitor therapy to endoscopic therapy had similar benefit. We hypothesized that an
adjuvant use of standard dose of proton pump inhibitor after combined endoscopic hemostasis
therapy offer similar benefit as high dose proton pump inhibitor did.
Eligibility
Minimum age: 16 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- adults aged above 16 years old with acute nonvariceal upper gastrointestinal bleeding
- read, agree to attend the study, and signed informed consent indicated to receive
esophagogastroduodenoscopy(EGD)
- peptic ulcers with high risk lesions (active bleeding: spurting, oozing peptic
ulcers. Ulcers with NBVV: nonbleeding visible vessel)
Exclusion Criteria:
- unable to receive EGD (unable to open mouth, upper gastrointestinal obstruction)
- bleeding tendency (platelet < 50x109/L, prothrombin time INR >2, ongoing use of
heparin or coumadin)
- gastric malignancy
- myocardial infarction within recent one week
- recent cerebrovascular event within recent one week
- pregnancy
- refuse to attend the study
- known allergy history to epinephrine or pantoprazole
Locations and Contacts
Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com
National Taiwan University Hospital, Taipei, Taiwan; Recruiting Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com
Additional Information
Starting date: January 2008
Last updated: July 2, 2008
|